Head to Head Survey: Bullfrog AI (NASDAQ:BFRG) & Ginkgo Bioworks (NYSE:DNA)

Bullfrog AI (NASDAQ:BFRG) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Bullfrog AI and Ginkgo Bioworks, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	1	0	0	1.50
Ginkgo Bioworks	2	2	0	0	1.50

Ginkgo Bioworks has a consensus target price of $7.00, suggesting a potential downside of 29.82%. Given Ginkgo Bioworks’ higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than Bullfrog AI.

Risk and Volatility

Bullfrog AI has a beta of -2.73, meaning that its share price is 373% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Insider & Institutional Ownership

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bullfrog AI and Ginkgo Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Valuation and Earnings

This table compares Bullfrog AI and Ginkgo Bioworks”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120,000.00	76.29	-$6.50 million	($0.46)	-1.07
Ginkgo Bioworks	$170.15 million	3.95	-$312.76 million	($5.01)	-1.99

Bullfrog AI has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Summary

Ginkgo Bioworks beats Bullfrog AI on 6 of the 11 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.